ArticleScientific reports2025
Interaction effects between serum 25(OH)D and CRP status on cancer related mortality in adult cancer survivors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Early C-reactive protein reduction predicts survival in real-world extensive-stage small cell lung cancer treated with first-line adebrelimab-based immunotherapy.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D deficiency and elevated CRP (C-reactive protein) levels are independent indicators of risk for mortality in cancer survivors; however, their combined association with mortality has not been examined. This study included adult cancer survivors from four NHANES cycles (2003-2010), utilizing a multistage survey design. CRP levels were measured using a latex-enhanced turbidimetric assay, and serum 25(OH)D levels were assessed using RIA and LC-MS/MS methods. Mortality data were linked with the National Death Index up to 2019. The restricted cubic spline model was used to explore the nonlinear associations with mortality. Kaplan-Meier analysis was used to examine survival curve differences. Cox analysis was employed to assess mortality risk after adjusting for confounding factors, and interaction analysis was conducted. Of the 1619 adult cancer survivors (56.9% female; weighted age 64.91 ± 0.44 years), 762 deaths were recorded during the 17-year follow-up. Higher CRP and lower 25(OH)D levels were associated with increased risks of all-cause and cancer mortality. Joint analysis revealed the High CRP and Low VID group had the highest all-cause (HR 2.40, 95% CI 1.82-3.17) and cancer (HR 5.23, 95% CI 3.15-8.70) mortality risk compared to Low CRP and High VID group. Additionally, a multiplicative interaction between serum 25(OH)D and CRP factors on cancer mortality was observed (P = 0.049), indicating a synergistic effect of these two factors on cancer mortality. Sex and ethnicity subgroup analyses revealed that the High CRP and Low VID group exhibits the highest risk for all-cause and cancer mortality, findings that are consistent with those observed in the overall population. In cancer survivors, an elevated risk of cancer and all-cause mortality is linked to vitamin D deficiency and elevated levels of CRP. In particular, the interaction between these factors may impact cancer survivors' mortality related to cancers. Consequently, the risks may be significantly reduced through the use of anti-inflammatory medications as well as adequate intake of vitamin D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.